Comparative Pharmacology
Head-to-head clinical analysis: PEMETREXED DISODIUM versus PEMFEXY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEMETREXED DISODIUM versus PEMFEXY.
PEMETREXED DISODIUM vs PEMFEXY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Pemetrexed is a folate analog metabolic inhibitor that disrupts folate-dependent metabolic processes essential for cell replication. It inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), thereby inhibiting de novo synthesis of thymidine and purine nucleotides.
Pemetrexed inhibits thymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT), which are folate-dependent enzymes involved in nucleotide synthesis, leading to disruption of DNA and RNA synthesis.
500 mg/m2 intravenously over 10 minutes on Day 1 of each 21-day cycle, with vitamin B12 and folic acid supplementation.
500 mg/m2 intravenously over 10 minutes on day 1 of a 21-day cycle, in combination with cisplatin.
None Documented
None Documented
Terminal half-life is 3.5 hours in patients with normal renal function. Increases in renal impairment (up to 20 hours if CrCl <45 mL/min).
Terminal elimination half-life ~17 hours (range 13-26 hours) in patients with normal renal function; prolonged to >24 hours in renal impairment. Supports every-21-day dosing.
Primarily renal excretion (70-90% as unchanged drug within 24 hours). Biliary/fecal excretion accounts for <5%.
Renal excretion (70-90% unchanged drug), biliary/fecal (<5%)
Category C
Category C
Antineoplastic Antifolate
Antineoplastic Antifolate